3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
CNS
3
Lymphoid
2
Head & Neck
2
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Melanoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Pathologic Complete Response
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
Cyclophosphamide
6
Radiotherapy
5
olaparib
3
exemestane
3
Paclitaxel
3
Letrozole
3
Itraconazole
3
Gemcitabine
3
Fulvestrant
3
Carboplatin
3
Blood Specimen Collection
3
palbociclib
2
fludarabine phosphate
2
eribulin
2
avelumab
2
abemaciclib
2
Therapeutics
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Mastectomy
2
Flow Cytometry
2
Filgrastim
2
Exercise
2
Everolimus
2
Etoposide
2
Dasatinib
2
Cetuximab
2
Carmustine
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
cemiplimab
×
Breast
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled